CLINICAL TRIALS PROFILE FOR GLIPIZIDE AND METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for GLIPIZIDE AND METFORMIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00513630 ↗ | Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease | Completed | Shanghai Jiao Tong University School of Medicine | Phase 4 | 2004-06-01 | The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study The end point of this study is: 1. follow up 3yr 2. recurrence of cardiovascular event 3. death caused by other reasons such as stroke, uremia, blindness and amputation |
| NCT00648505 ↗ | Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fed conditions. |
| NCT00649454 ↗ | Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting conditions. |
| NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | Bristol-Myers Squibb | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
| NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | AstraZeneca | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
| NCT00696982 ↗ | The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation | Unknown status | Assaf-Harofeh Medical Center | N/A | 2008-06-01 | Recently a new category of antihyperglycemic therapy aiming to modulate the incretin system has emerged. These drugs induce insulin secretion without inducing hypoglycemia. The effect of the incretin modulators drugs on hypertension, arterial stiffness, inflammation and oxidative stress parameters have not been fully investigated yet.GLP-1 analogue has been suggested to have an effect on endothelium and the development of hypertension. Nystrom et al have demonstrated that GLP-1 improves endothelial dysfunction in a small group of type 2 diabetes subjects, with coronary heart disease. We hypothesize that DPP-4 inhibitor will have an effect on hypertension and arterial stiffness by effect on the NO pathway.The aim of this study is to investigate the effect of two insulin inducers drugs, sulfonyl urea and DPP-4 inhibitor on 24 hours blood pressure monitoring, arterial stiffness, oxidative stress and inflammation. |
| NCT00834587 ↗ | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2004-06-01 | This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult subjects administered under non-fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GLIPIZIDE AND METFORMIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for GLIPIZIDE AND METFORMIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for GLIPIZIDE AND METFORMIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for GLIPIZIDE AND METFORMIN HYDROCHLORIDE
Sponsor Name
